Femasys Inc. Secures $400,000 Order for FemBloc in Spain, Marking First European Market Entry
Reuters
Aug 06
Femasys Inc. Secures $400,000 Order for FemBloc in Spain, Marking First European Market Entry
Femasys Inc. has announced a significant milestone in its global expansion efforts with its first commercial entry into Europe. The company secured an order valued at approximately $400,000 USD for its FemBloc Permanent Birth Control in Spain, marking the country as the first to establish a distribution partnership. FemBloc is a groundbreaking non-surgical permanent contraceptive that uses a patented delivery system to safely block fallopian tubes, eliminating the risks associated with surgical sterilization. This development follows a collaboration with Spanish partners Comercial Medico Quirúrgica and Durgalab, who are poised to navigate both public and private healthcare systems to implement FemBloc efficiently. Femasys is focused on scaling production to meet the anticipated demand as interest grows across Europe.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506811-en) on August 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.